Major Adverse Cardiac Events in Pregnant Women with Surgically Treated Hypertrophic Cardiomyopathy

Overview

About this study

The purpose of this study is:

  • To ascertain the prevalence of major adverse cardiac events during pregnancy in patients with history of surgically corrected hypertrophic cardiomyopathy
  • To determine the major adverse cardiac events (mortality, arrhythmias, hear failure, endocarditis, pulmonary embolism, myocardial infarction etc) in pregnant women after surgical correction of hypertrophic cardiomyopathy
     

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Women of reproductive age group (15-49 years) who have undergone surgical correction of hypertrophic cardiomyopathy

Exclusion Criteria: 

  • Women who did not conceive
  • Pre-mature menopause
  • No research consent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Hartzell Schaff, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions